US Patent

US12390540 — Dual mode radiotracer and -therapeutics

Composition of Matter · Assigned to Technische Universitaet Muenchen Klinikum Rechts Der Isar · Expires 2038-08-23 · 12y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a single molecule that combines a disease-targeting ligand, a silicon-fluoride acceptor, and one or more chelating groups.

USPTO Abstract

The present invention relates to a ligand-SIF A-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

Drugs covered by this patent

Patent Metadata

Patent number
US12390540
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-08-23
Drug substance claim
Yes
Drug product claim
No
Assignee
Technische Universitaet Muenchen Klinikum Rechts Der Isar
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.